Payment overview · 2025
General Payments
$1,111.21
71 reported records · 19 companies
Healthcare provider profile · identity verified
Charles Bolick, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRISTOL, TN · NPI 1609870583
Verified facts
What the public records show
CMS Open Payments records show Charles Bolick, MD received $1,111.21 in general payments during 2025 across 71 reported records.
ABBVIE INC. accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 308 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $237.36 | 21.4% | 18 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $223.00 | 20.1% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.70 | 12.4% | 10 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $117.39 | 10.6% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $52.66 | 4.7% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $48.31 | 4.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.28 | 4.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.85 | 3.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.14 | 3.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.70 | 2.6% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $23.80 | 2.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.28 | 1.8% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $15.18 | 1.4% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $14.24 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.12 | 1.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.01 | 1.3% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $13.93 | 1.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.66 | 1.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.60 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,111.21 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $223.00 | 16 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $181.92 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $158.93 | 12 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $117.39 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.43 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $61.27 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.14 | 6 | 2025 |
Source payment records
|
|||||
| General - Erectile Dysfunction Normalized: general erectile dysfunction |
Device | Boston Scientific Corporation | $52.66 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $48.31 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $47.28 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $43.75 | 4 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $42.85 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.14 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.70 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $11.69 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $11.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
161 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
308 | 52 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 434 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 409 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 404 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 399 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 351 | 91 |
| Lisinopril | Lisinopril | 337 | 91 |
| Eliquis | Apixaban | 308 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 307 | 83 |
| Gabapentin | Gabapentin | 302 | 73 |
| Furosemide | Furosemide | 279 | 79 |
| Pregabalin | Pregabalin | 275 | 49 |
| Metformin Hcl | Metformin Hcl | 271 | 70 |
| Tramadol Hcl | Tramadol Hcl | 269 | 57 |
| Benazepril Hcl | Benazepril Hcl | 262 | 57 |
| Omeprazole | Omeprazole | 252 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 238 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 233 | 54 |
| Meloxicam | Meloxicam | 227 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 58 |
| Alprazolam | Alprazolam | 203 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 50 |
| Famotidine | Famotidine | 174 | 41 |
| Clonazepam | Clonazepam | 172 | 22 |
| Losartan Potassium | Losartan Potassium | 171 | 45 |
| Sertraline Hcl | Sertraline Hcl | 164 | 38 |
| Jardiance | Empagliflozin | 161 | 31 |
| Metformin Hcl Er | Metformin Hcl | 152 | 47 |
| Carvedilol | Carvedilol | 143 | 33 |
| Simvastatin | Simvastatin | 142 | 36 |
| Buspirone Hcl | Buspirone Hcl | 141 | 30 |
| Trazodone Hcl | Trazodone Hcl | 141 | 35 |
| Allopurinol | Allopurinol | 133 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 23 |
| Prednisone | Prednisone | 130 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 126 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 120 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 119 | 29 |
| Farxiga | Dapagliflozin Propanediol | 118 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 113 | 23 |
| Bupropion Xl | Bupropion Hcl | 105 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 22 |
| Montelukast Sodium | Montelukast Sodium | 99 | 27 |
| Baclofen | Baclofen | 98 | 24 |
| Spironolactone | Spironolactone | 97 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 96 | 18 |
| Glimepiride | Glimepiride | 93 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 25 |
| Cephalexin | Cephalexin | 84 | 34 |
| Donepezil Hcl | Donepezil Hcl | 82 | 22 |
| Potassium Chloride | Potassium Chloride | 82 | 23 |
| Valsartan | Valsartan | 80 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 79 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 75 | 14 |
| Lorazepam | Lorazepam | 74 | 11 |
| Ozempic | Semaglutide | 71 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 14 |
| Atenolol | Atenolol | 69 | 19 |
| Finasteride | Finasteride | 68 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 15 |
| Trulicity | Dulaglutide | 64 | suppressed |
| Fenofibrate | Fenofibrate | 63 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 63 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 42 |
| Eszopiclone | Eszopiclone | 59 | 14 |
| Estradiol | Estradiol | 58 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 56 | 14 |
| Promethazine Hcl | Promethazine Hcl | 56 | 16 |
| Ondansetron Odt | Ondansetron | 55 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | 13 |
| Celecoxib | Celecoxib | 52 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 13 |
| Ibuprofen | Ibuprofen | 51 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 11 |
| Mounjaro | Tirzepatide | 51 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 51 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 20 |
| Doxepin Hcl | Doxepin Hcl | 49 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 13 |
| Meclizine Hcl | Meclizine Hcl | 42 | 17 |
| Mirtazapine | Mirtazapine | 42 | 11 |
| Chlorthalidone | Chlorthalidone | 41 | suppressed |
| Entresto | Sacubitril/Valsartan | 40 | 11 |
| Levetiracetam | Levetiracetam | 40 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 39 | suppressed |
| Irbesartan | Irbesartan | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 32 |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 11 |
| Naproxen | Naproxen | 34 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 33 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 14 |
| Ramipril | Ramipril | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Nabumetone | Nabumetone | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Mupirocin | Mupirocin | 21 | 17 |
| Silodosin | Silodosin | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 14 |
| Colchicine | Colchicine | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Tramadol Hcl Er | Tramadol Hcl | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Droplet Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,111.21 · 71 records | ABBVIE INC. | Auvelity, Azstarys, CREON, ETERNA, GVOKE HYPOPEN, General - Erectile Dysfunction, Heplisav-B, IBSRELA, INGREZZA, INJECTAFER, LEQVIO, LINZESS, LifeVest, MOUNJARO, NURTEC ODT, Natroba, Ozempic, QULIPTA, Rybelsus, Spinosad, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, VYEPTI, Veozah, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error